Not a Member? Register Now
Email this page
Send the page "" to a friend, relative, colleague or yourself.
Separate multiple email address with a comma
We do not record any personal information entered above.
Thank you. Your email has been sent.
FDA Date: 03/21/2017
Gattex (teduglutide [rDNA origin]) Injection REMS
Goals of the Gattex (teduglutide [rDNA origin]) Injection REMS Program
The goals of the GATTEX REMS are to mitigate the risks of possible acceleration of neoplastic growth and enhancement of colon polyp growth, gastrointestinal obstruction, and biliary and pancreatic disorders associated with GATTEX by: • Informing patients about the risks listed above associated with the use of GATTEX • Informing healthcare providers about the risks listed above associated with GATTEX
• Elements to Assure Safe Use